LGVN Q2 2022 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$18M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$466,000-4.7% YoY

Gross Profit

$160,00034.3% margin

Operating Income

-$4M-905.8% margin

Net Income

-$6M-1206.9% margin

EPS (Diluted)

$-2.70

QoQ Revenue Growth

+25.9%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$900,000

Balance Sheet

Total Assets

$35M

Total Liabilities

$6M

Stockholders' Equity

$29M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$466,000	$489,000	-4.7%
Gross Profit	$160,000	$208,000	-23.1%
Operating Income	-$4M	-$5M	+16.6%
Net Income	-$6M	-$5M	-12.3%